Business Wire

GSOA

15.12.2021 17:35:10 CET | Business Wire | Press release

Share
Satellite Operators join to shape the communications ecosystem of the future through the transformation of the EMEA Satellite Operators’ Association to the Global Satellite Operators’ Association

Chief Executives of the world’s leading satellite operators announced today in Paris on the occasion of World Satellite Business Week 2021 that ESOA, the EMEA Satellite Operators Association, is expanding to include satellite operators from all world regions and will change its name to GSOA, the Global Satellite Operators’ Association. They also announced that seven new members – Amazon, APT, ARSAT, Intersputnik, Lockheed Martin, Omnispace and Star One – had already agreed to join GSOA.

GSOA will remain the only CEO-driven satellite industry association. It will focus on a core mission of providing a unified voice and a platform for collaboration for satellite operators globally to ensure their continued success and for broadening the opportunities for policymakers and industry players to leverage satellite services to fulfil their objectives.

“The creation of GSOA reflects a strong belief in the satellite communications sector that a strong, global voice is needed to ensure that the sector is well positioned to helping create a more connected and sustainable world,” said Stephen Spengler, ESOA Chairman and CEO of Intelsat. “The fact that new members are already joining us is a demonstration of support for GSOA’s mission and the need to ensure that, together, we have a strong voice in shaping the communications ecosystem of the future.”

Leading Change

GSOA is structured to drive industry leadership in the face of three key trends: unparalleled innovation in the space sector, an insatiable demand for all types of connectivity, and a need to bring sustainability to space. In this regard, the GSOA Board has approved three broad industry goals.

GSOA is committed to:

On earth: extending connectivity globally where other networks don’t, connecting unconnected communities, schools, households, planes, ships, businesses, humanitarian agencies, peacekeepers and governments, aiming to increase the number of satellite data connections by 250% by 2030 and increase the data consumed by those connections 15 fold.

In space: preserving the space environment for future generations by designing, launching and operating satellites in a responsible way and minimising the creation of space debris.

For all: supporting the UN Sustainable Development Goals by providing access to secure, reliable and sustainable broadcast & broadband connectivity to people, schools, enterprises, organisations and devices wherever they may be, whether on the move, at work, or at play.

ESOA to GSOA

With the industry’s multi-orbit offering, the satellite sector will respond to the great majority of connectivity requirements presented by the data driven economy of tomorrow. From bridging crippling social, education, healthcare and other divides that exist due to the lack of communications infrastructure on all continents to enabling a host of 5G and IoT use cases for different vertical sectors.

Satellite operators will continue to build on the successes of ESOA which include providing the support the industry needed to push ahead with 5G standards and vital leadership on issues such as satellite spectrum and space sustainability. Through GSOA, the satellite sector will now be able to drive such global activities leveraging a global operator base.

GSOA will provide its members with the opportunity to shape the future of the satellite communications industry and the frameworks in which it operates by participating in key activities that impact the sector. Specifically, GSOA members will be able to engage in cross-sector initiatives, drive common positions, represent the industry on topics such as spectrum and 5G in events on all continents and contribute to ITU work concerning the development agenda, emergency communications and of course spectrum.

The association will continue to have a CEO-led Board, which has proved invaluable to the success of the ESOA to date, a strong Secretariat, and member-driven working groups that execute the broad agenda set by the Board.

This is an important change that will help ensure the industry is positioned well into the future ”, said Aarti Holla-Maini, the secretary general of ESOA. “We also recognize that there are other industry associations who will want to understand the implications of this change and we look forward to working with them to ensure the satellite communications sector has the strongest possible, unified global voice .”

The Global Satellite Operators Association now counts among its members: Airbus CIS, Amazon, Amos Spacecom, APT, Arabsat, Arsat, Avanti, Azercosmos, Echostar-Hughes, HellasSat, Hispasat, Inmarsat, Intelsat, Intersputnik, Lockheed Martin, Nigcomsat, Nilesat, Omnispace, OneWeb, Rascomstar, SES, SSI-Monacosat, Star One, Telenor, Telesat, Telespazio, Thuraya, Turksat, Viasat and Yahsat as well as representatives of the broader space industry including Airbus Defence and Space, Arianespace, Astroscale, Mansat, ST Engineering and Thales Alenia Space.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye